Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Screening Period	STARTED	Eculizumab	23
Screening Period	COMPLETED	Eculizumab	20
Screening Period	NOT COMPLETED	Eculizumab	3
Observation Period (8 Weeks)	STARTED	Eculizumab	20
Observation Period (8 Weeks)	COMPLETED	Eculizumab	20
Observation Period (8 Weeks)	NOT COMPLETED	Eculizumab	0
Treatment Period (26 Weeks)	STARTED	Eculizumab	20
Treatment Period (26 Weeks)	COMPLETED	Eculizumab	20
Treatment Period (26 Weeks)	NOT COMPLETED	Eculizumab	0
Extension Treatment Period	STARTED	Eculizumab	19
Extension Treatment Period	COMPLETED	Eculizumab	18
Extension Treatment Period	NOT COMPLETED	Eculizumab	1
Post Treatment Period (Patients Who Disc	STARTED	Eculizumab	5
Post Treatment Period (Patients Who Disc	COMPLETED	Eculizumab	4
Post Treatment Period (Patients Who Disc	NOT COMPLETED	Eculizumab	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00844428/flow